Wheatley Group

The Wheatley group seeks to increase our understanding of immunity to SARS-CoV-2, Influenza and other pandemic viruses, in order to facilitate rational improvement of vaccination strategies and treatment paradigms. With a primary focus on humoral aspects of immunity, we aim:

• To explore immunological mechanisms that underpin successful vaccination, including the factors that maximise the protective efficacy, breadth and durability of anti-viral immunity.
• To design, develop and clinically assess the next-generation of vaccine platforms and regimens, including self-assembling nanoparticle and mRNA-based technologies.
• To discover, optimise and clinically develop human/humanised monoclonal antibodies as potent antiviral drugs for treatment or prevention of viral infectious diseases.